Category: Johnson & Johnson

Johnson & Johnson posts Phase 3 win for lung cancer therapy

JHVEPhoto The Janssen unit of Johnson & Johnson (NYSE:JNJ) announced Thursday that its bispecific antibody Rybrevant in a combination regimen outperformed AstraZeneca’s (AZN) tyrosine kinase inhibitor osimertinib as a first-line therapy in certain patients with lung cancer. Citing topline data, Janssen said that its pivotal Phase 3 MARIPOSA study met…

Continue Reading Johnson & Johnson posts Phase 3 win for lung cancer therapy

Johnson & Johnson’s Janssen Says Phase 3 Trial of Rybrevant Plus Chemotherapy in Lung Cancer Meets Primary Endpoint

Johnson & Johnson is one of the world’s leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.5%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment…

Continue Reading Johnson & Johnson’s Janssen Says Phase 3 Trial of Rybrevant Plus Chemotherapy in Lung Cancer Meets Primary Endpoint

DNA Sequencing and Service Market 2023 Trends with Analysis on Key Players Roche Johnson & Johnson Illumina Thermo Fisher Scientific Beckman Coulter Pacific Biosciences Oxford Nanopore GE Healthcare Life Sciences Abbott Laboratories

The research project on the global DNA Sequencing and Service market offers a thorough analysis of marketplace patterns, drivers, challenges, and opportunities. It includes a variety of market segments, including the type of product, the application, end users, and geography, to give a comprehensive picture of the market’s performance. A…

Continue Reading DNA Sequencing and Service Market 2023 Trends with Analysis on Key Players Roche Johnson & Johnson Illumina Thermo Fisher Scientific Beckman Coulter Pacific Biosciences Oxford Nanopore GE Healthcare Life Sciences Abbott Laboratories

Roche, Johnson & Johnson, Illumina, Thermo Fisher Scientific

PRESS RELEASE Published April 19, 2023 New Jersey, N.J. A2Z Market Research announces the release of DNA Sequencing and Service Market research report. The market is predicted to grow at a healthy pace in the coming years. DNA Sequencing and Service Market 2023 research report presents an analysis of market…

Continue Reading Roche, Johnson & Johnson, Illumina, Thermo Fisher Scientific

Johnson & Johnson Halts Phase 3 RSV Vaccine Trial

This week, the Janssen Pharmaceutical Companies of Johnson & Johnson announced it had stopped its EVERGREEN phase 3 trial for its RSV investigational vaccine that was developed for adults 60 years and older. The company said it decided to do so after reviewing the current adult RSV market. “By periodically…

Continue Reading Johnson & Johnson Halts Phase 3 RSV Vaccine Trial

Johnson & Johnson Discontinues Phase 3 Study Evaluating Respiratory Syncytial Virus Vaccine

Dr_Microbe – stock.adobe.com The Janssen Pharmaceutical Companies of Johnson & Johnson announced that it will discontinue its phase 3 EVERGREEN (NCT04908683) study evaluating an investigational respiratory syncytial virus (RSV) vaccine, according to a statement by the company.1 “By periodically refocusing our portfolio, Janssen ensures that we are deeply invested in…

Continue Reading Johnson & Johnson Discontinues Phase 3 Study Evaluating Respiratory Syncytial Virus Vaccine

Johnson & Johnson’s dengue antiviral drug shows positive results

Novel anti-viral drug developed by Johnson & Johnson (J&J) arm Janssen Pharmaceutical provides “strong protection” against dengue in non-human primates and mice, early stage clinical data published in ‘Nature’ journal has revealed. “The first-in-class antiviral, which was shown to be safe and…

Continue Reading Johnson & Johnson’s dengue antiviral drug shows positive results

Latest Innovations, Drivers and Industry Key Events 2021-2027 I Top key players-Recursion Pharmaceuticals, Inc, IntraBio Inc, Johnson & Johnson Services,& Others. – The Manomet Current

“The global Tay-Sachs Disease Market was worth USD billion in 2019 and is expected to grow to USD billion by 2027, with a CAGR of %. from 2020 to 2027. Over the review period, advances in technology and improved systems will drive growth in the Tay-Sachs Disease Market industry. Get…

Continue Reading Latest Innovations, Drivers and Industry Key Events 2021-2027 I Top key players-Recursion Pharmaceuticals, Inc, IntraBio Inc, Johnson & Johnson Services,& Others. – The Manomet Current